Bellerophon Therapeutics, Inc. in its Annual meeting of shareholders held on June 1, 2022 elected Mary Ann Cloyd and Crispin Teufel to serve on the Company's board of directors for a three-year term until the Company's 2025 annual meeting of stockholders and until each of their respective successors is duly elected and qualified.